Related Experiment Videos

[Therapeutical strategies in hypertensive patients presenting heart failure symptoms]

Christian Ebner1

  • 1II. Interne Abteilung mit Kardiologie und Angiologie und Intensivstation, A.ö. Krankenhaus der Elisabethinen Linz, Linz, Osterreich. christian.ebner@elisabethinen.or.at

Wiener Medizinische Wochenschrift (1946)
|March 9, 2004
PubMed

Insights

Congestive heart failure (CHF) management has evolved, with ACE-inhibitors and beta-blockers now essential. New trials show combined therapies, including Angiotensin-II-receptor blockers, further reduce mortality in CHF patients.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Public Health

Background:

  • Congestive heart failure (CHF) is a growing global health concern.
  • Coronary artery disease is now a primary cause of CHF, with hypertension, diabetes, and hyperlipidemia as key risk factors.
  • Non-pharmacological interventions like fluid restriction and exercise are important for stable CHF.

Purpose of the Study:

  • To review current pharmacological treatments for congestive heart failure.
  • To highlight the role of specific drug classes in reducing CHF mortality.
  • To emphasize the importance of managing underlying risk factors like hypertension.

Main Methods:

  • Review of recent large double-blind randomized trials on CHF pharmacotherapy.
  • Analysis of drug efficacy in reducing mortality and managing symptoms.
  • Focus on ACE-inhibitors, beta-blockers, Angiotensin-II-receptor blockers, and diuretics.

Main Results:

  • ACE-inhibitors and beta-blockers are foundational treatments for CHF.
  • Angiotensin-II-receptor blockers offer an alternative when ACE inhibitors or beta-blockers are not tolerated.
  • The CHARM study demonstrated further mortality reduction with the combination of all three drug classes.
  • Diuretics are crucial for managing fluid overload in progressive heart failure.

Conclusions:

  • Aggressive treatment of hypertension is critical for preventing heart failure development.
  • Pharmacological interventions, particularly ACE-inhibitors and beta-blockers, significantly reduce CHF mortality.
  • Combined therapy with ACE-inhibitors, beta-blockers, and Angiotensin-II-receptor blockers offers additional survival benefits.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...